Glucagon-like peptide-1 (GLP-1) receptor agonists and other anti-obesity pharmacotherapies are widely acknowledged as supplementary alternatives for weight management in women with polycystic ovarian syndrome (PCOS) when lifestyle modifications prove inadequate. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.